focus -WSS

focus

author：focus 2025-09-06 02:05:50 - browse：48

Adam's take main illustration — Molly Ferguson/STAT

Behind the stellar commercial launch of Amylyx Pharmaceuticals’ treatment for ALS lies an uncomfortable question: Does early success of the drug, called Relyvrio, make it more complicated, perhaps impossible, to pull it from the market if we find out next year that it doesn’t work?

On Monday night, Amylyx said Relyvrio sales totaled $22 million in 2022 — a period that covers slightly more than one calendar quarter given the drug’s U.S. approval last September. The company said approximately 1,300 ALS patients were on Relyvrio at the end of December, and it expects that number to at least double by the end of the first quarter.

“We’re probably going to double, closer to triple, our revenue in Q1,” said James Frates, Amylyx’s chief financial officer, speaking on Monday night’s conference call.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： The Pandemic Treaty must support building strong health systems

WSS

My daughter's legacy lives on through her writing, phage therapy

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

My daughter's legacy lives on through her writing, phage therapy

Cigna wins case to block Amy Bricker's move to CVS

Cigna wins case to block Amy Bricker's move to CVS

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

focus

focus

knowledge

Jerome Adams on the need for new antivirals for Covid

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

What does generative AI mean for health care? We asked experts

Coercive sterilizations revealed by STAT prompt outrage

Wildfire smoke exposes gaps in outdoor worker protections

Ionis drug prevents swelling attacks due to hereditary angioedema

Psychedelics group wrestles with new pharma identity

Report captures long Covid’s disabling effects and policy challenges

Hollywood unions extend contract negotiations for actors

Study: Why relieving medical debt did not improve financial outcomes

Wikipedia

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

Cord blood banking comes at a high cost to babies

Stephen Quake on the Chan Zuckerberg quest to conquer disease

See how much Covid

Ionis drug prevents swelling attacks due to hereditary angioedema

entertainment

focus

Wikipedia

Wikipedia